Co-CEOs: A new trend?

Julien Willard
October 2, 2025
1 min read
Share this post

Given my intelligence background, I get hired to profile leadership teams before PE/VC firms invest.

My observation (entirely empirical) suggests PE firms that understand who they're investing in perform better long-term.

I've seen it all: timid biotech scientists playing CEO, narcissists, sociopaths, egomaniacs, misogynists. And more.

Early-stage biotech typically runs on excellent scientists with brilliant ideas.

TechBio companies lean on stellar technologists.

What these small firms often lack? A sharp business operator with three critical skills:

— Strategic decision-making under uncertainty - evaluating complex information and making calls with incomplete data about markets, regulations, and competitors

— Cross-functional integration - coordinating across scientific, commercial, regulatory, and financial functions while managing limited resources

— Network-based market intelligence - leveraging relationships to gather information about customers, competitors, partners, and regulatory pathways

Academic research (look up Harvard Business Review) shows co-CEOs deliver 9.5% annual returns versus 6.9% for market indices.In biotech? It gets quite complicated.

Take Amylyx Pharmaceuticals. Co-CEOs Joshua Cohen and Justin Klee built something remarkable—until their ALS drug hit regulatory walls. Stock plunged 79% this year.

Summit Therapeutics, Inc. tells a different story. Their co-CEOs just bought $12M of their own shares after Phase III results.

Co-CEOs make decisions differently. When Amylyx's leaders disagree, they don't power struggle -- they gather more data. That's gold in an industry where 90% of programs fail.Biotech's future belongs to leaders who navigate both scientific uncertainty and commercial reality.

Whether that's one person or two depends on the challenge.

The question isn't whether co-CEOs work in biotech. It's whether your organization has complexity demanding shared expertise - and the governance structure to support it.

***Want to understand if your leadership team fits your business goals? My colleagues (or I) can map out a behavioral profiling exercise for you.

The economics of the business and the psychology of its leaders go hand in hand.

Illustration by Paul Blow.

Share this post
Executives
Behavior Profile
Commercial Strategy
Investments
Biotech
Oncology
Healthcare Trends
Consulting Tips
Industry Insights
Pharmaceutical Strategy
Julien Willard
Julien Willard

Stay Updated with Our Insights

Subscribe to receive the latest blog posts and valuable insights from the pharmaceutical industry.

Blog

Short heading goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

View all
No items found.

FAQs

Here are some common questions about our blog posts and their content.
What topics are covered?

Our blog covers a range of topics relevant to the pharmaceutical industry, including strategy insights, market trends, and case studies. Each post aims to provide valuable information that can aid decision-making. We also explore innovative practices that can enhance operational efficiency.

How often are posts published?

New blog posts are published bi-weekly to ensure fresh and relevant content. This schedule allows us to dive deep into each topic while maintaining high-quality standards. Subscribers can expect timely updates directly in their inbox.

Can I contribute ideas?

Absolutely! We welcome contributions and suggestions from our readers. If you have a topic in mind that you believe would benefit our audience, please reach out. Collaboration is key to enriching our community.

Is there a newsletter?

Yes, we offer a newsletter that highlights our latest blog posts and industry insights. Subscribers receive exclusive content and updates straight to their inbox. Sign up to stay informed and engaged.

How can I contact?

You can reach out through our contact form available on the website. We encourage questions, feedback, and inquiries about our services. Your engagement is important to us.